세계 장기 칩 시장 규모는 2023년 1억 990만 달러에서 2033년 35억 9,630만 달러에 달할 것으로 예상되며, 예측 기간인 2024-2033년 CAGR은 42.09%에 달할 것으로 예측됩니다.
세계 장기 칩 시장의 성장을 촉진하는 주요 요인으로는 신약 개발, 독성 테스트, 미세유체공학 분야의 지속적인 기술 발전이 있습니다. 조직공학, 미세유체공학, 세포생물학의 결합은 마이크로 엔지니어링을 통한 장기칩(OOC) 플랫폼 개발에 기여하고 있습니다. 막대한 R&D 투자와 정부 기관 및 OOC 진입 기업과의 협력은 시장 성장에 더욱 기여하고 있습니다.
| 주요 시장 통계 | |
|---|---|
| 예측 기간 | 2024-2033년 |
| 2024년 평가 | 1억 5,240만 달러 |
| 2033년 전망 | 35억 9,630만 달러 |
| CAGR | 42.09% |
세계 장기 칩 시장은 기기 시스템, 칩 및 마이크로 유체 장치, 소모품, 소프트웨어 및 데이터 분석 도구와 같은 제품 및 서비스 제품, 그리고 간 온 칩, 신장 온 칩, 폐 온 칩, 심장 온 칩, 뇌 온 칩, 기타 장기 칩과 같은 장기 유형으로 구성됩니다.
장기 칩 시장에서는 의약품 개발 및 개인 맞춤형 의료에 대한 첨단 솔루션의 필요성으로 인해 주요 기업 간의 파트너십이 눈에 띄게 증가하고 있습니다. 각 기업이 서로의 기술적 전문 지식과 시장에서의 입지를 활용하기 위해 협력적 노력이 확산되고 있습니다. 예를 들어, 제약회사와 생명공학 기업 간의 제휴는 혁신적인 장기 칩 기술을 주요 의약품 검사 프로세스에 통합하는 것을 촉진하고 있습니다. 이러한 제휴는 연구 역량을 강화할 뿐만 아니라 장기 칩 플랫폼의 상용화를 가속화하고 있습니다.
장기 칩 시장은 투자와 자금 조달이 급증하고 있으며, 이는 이 기술이 의약품 개발 및 개인 맞춤형 의료에 혁명을 일으킬 수 있다는 확신이 높아졌음을 반영합니다. 벤처캐피털, 비상장 기업, 대형 제약사들은 장기 칩 플랫폼의 개발 및 상용화를 지원하기 위해 점점 더 많은 자금을 투입하고 있습니다. 이러한 자본의 유입으로 스타트업과 기존 기업 모두 연구개발을 가속화하고, 기술 역량을 확대하며, 혁신적인 솔루션을 보다 빠르게 시장에 출시할 수 있게 되었습니다.
이 보고서는 세계 장기 칩 시장을 조사하여 시장 개요와 함께 제공별, 장기 유형별, 용도별, 최종사용자별, 국가별 동향, 시장 진입 기업 개요 등을 제공합니다.
범위와 정의
Introduction to the Organ-on-Chip Market
The global organ-on-chip market is projected to reach $3,596.3 million by 2033 from $109.9 million in 2023, growing at a CAGR of 42.09% during the forecast period 2024-2033. The key factors driving the growth of the global organ-on-chip market include continuous technological advancements in the fields of drug discovery, toxicity testing, and microfluidics. The combination of tissue engineering, microfluidics, and cell biology has contributed to the development of a micro-engineered organ-on-chip (OOC) platform. Huge R&D investments and collaboration with government agencies and OOC players are further contributing to the market growth.
Market Introduction
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2024 - 2033 |
| 2024 Evaluation | $152.4 Million |
| 2033 Forecast | $3,596.3 Million |
| CAGR | 42.09% |
The global organ-on-chip market consists of products and services products such as instrument systems, chips or microfluidic devices, consumables, and software and data analysis tools, as well as organ types that include liver-on-a-chip, kidney-on-a-chip, lung-on-a-chip, heart-on-a-chip, brain-on-a- chip, and other organ-on-chip.
Impact Analysis:
The organ-on-chip market has made an impact in the following ways:
Increasing Partnerships among Players: The organ-on-chip market has been witnessing a notable increase in partnerships among key players, driven by the need for advanced solutions in drug development and personalized medicine. Collaborative efforts have become more prevalent as companies aim to leverage each other's technological expertise and market presence. For instance, partnerships between pharmaceutical giants and biotech firms are facilitating the integration of innovative organ-on-chip technologies into mainstream drug testing processes. These alliances are not only enhancing research capabilities but also accelerating the commercialization of organ-on-chip platforms.
Increasing Investment and Funding for Organ-on-Chip Technologies: The organ-on-chip market has been experiencing a surge in investment and funding, reflecting growing confidence in the technology's potential to revolutionize drug development and personalized medicine. Venture capitalists, private equity firms, and large pharmaceutical companies are increasingly allocating substantial resources to support the development and commercialization of organ-on-chip platforms. This influx of capital is enabling startups and established players alike to accelerate their research and development efforts, expand their technological capabilities, and bring innovative solutions to the market more rapidly.
Market Segmentation:
Segmentation 1: by Application
Drug Discovery Segment to Continue Dominating the Organ-on-Chip Market (by Application)
Based on application, the organ-on-chip market has been led by drug discovery, which held a 65.20% share in 2023.
Segmentation 2: by Offering
Product Segment to Continue Dominating the Organ-on-Chip Market (by Offering)
Based on offering, the organ-on-chip market has been led by product, which held a 53.94% share in 2023.
Segmentation 3: by Organ Type
Liver-on-a-Chip Segment to Continue Dominating the Organ-on-Chip Market (by Organ Type)
Based on organ type, the organ-on-chip market has been led by liver-on-a-chip, which held a 28.31% share in 2023.
Segmentation 4: by End User
Pharmaceutical and Biotechnology Companies Segment to Continue Dominating the Organ-on-Chip Market (by End User)
Based on end user, the organ-on-chip market has been led by pharmaceutical and biotechnology companies, which held a 72.69% share in 2023.
Segmentation 5: by Region
Rest-of- Asia-Pacific dominated the Asia-Pacific organ-on-chip market in 2023. This region includes fast-growing economies such as Indonesia and Thailand, where increased healthcare spending and governmental research support are beginning to foster market growth. Challenges across these markets include varying regulatory environments and sometimes limited local funding for high-tech research.
Recent Developments in the Organ-on-Chip Market
Demand - Drivers and Limitations
Market Demand Drivers:
Increasing Demand for Animal-Free Testing: The growing demand for animal-free testing methods has significantly advanced organ-on-chip technology. These systems, which replicate human organ functions in vitro, are revolutionizing biomedical research and pharmaceutical development. Their capability to mimic human physiology, coupled with long-term cost-efficiency and high-throughput screening, makes them essential tools in modern healthcare and drug discovery. Additionally, the customizable nature of organ-on-chip systems and their alignment with ethical and sustainable practices are expected to further drive innovation and adoption across various research domains.
Increasing Focus on Organ-on-Chip Technology: Organ-on-chip technology has been experiencing a surge in emphasis due to several factors. Ethical concerns surrounding animal testing are driving the search for alternatives, while the potential for improved accuracy in drug development compared to animal models is highly attractive. Additionally, organ-on-chip systems offer potential cost-effectiveness and faster drug discovery through the ability to test multiple compounds simultaneously.
Rising Adoption of Organ-on-Chip (OOC) Technology among Pharmaceutical and Biotechnology Companies: Pharmaceutical and biotechnology companies are increasingly adopting organ-on-chip (OOC) technology due to its transformative potential in drug development and biomedical research. These microfluidic platforms replicate human organ structure and function, providing a more physiologically relevant environment for studying disease mechanisms, drug responses, and toxicity. The growing adoption of OOC technology has been driven by several key factors.
Firstly, OOC platforms offer a more accurate and predictive model compared to traditional cell cultures or animal studies. This enhanced fidelity improves the reliability of preclinical testing, enabling more informed decision-making during drug development. Additionally, OOC systems present a cost-effective alternative to animal studies, reducing the time and resources needed for preclinical research.
Secondly, OOC technology supports high-throughput screening of drug candidates, allowing companies to simultaneously assess multiple compounds in a controlled microenvironment. This capability accelerates the drug discovery process and aids in identifying promising candidates for further development.
Market Challenges:
Limitation of Use Restricted to Preclinical Trials: The use of organ-on-chip (OOC) technology is currently limited primarily to preclinical trials, which could pose a significant constraint on its broader application in clinical settings. While OOC platforms offer remarkable advantages in mimicking human physiology and predicting drug responses, their use is restricted by regulatory and validation challenges. These technologies are yet to be fully integrated into clinical trial phases, as extensive validation and standardization are required to ensure their reliability and reproducibility in a clinical context.
Difficulty in Mimicking Complex Tissues and Organs: One of the significant challenges faced by organ-on-chip (OOC) technology is the difficulty in accurately mimicking complex tissues and organs. While OOC platforms have made impressive strides in replicating simpler organ functions, reproducing the intricate architecture and multifaceted interactions of complex tissues remains a formidable task. The limitations in current microfabrication techniques and biomaterials might hinder the development of fully functional models that precisely emulate the dynamic environment of human organs. Additionally, achieving the integration of multiple cell types and ensuring their long-term viability and functionality within the chip adds another layer of complexity.
Market Opportunities:
Development of Multi-Organ-on-Chip Systems: The development of multi-organ-on-chip (OOC) systems marks a significant stride in biomedical research and drug development. These systems integrate various organ-on-chip platforms into a unified device, enabling researchers to replicate the intricate interactions between different organs and study complex physiological responses more comprehensively. By simulating the interconnectedness and communication between organs, multi-organ-on-chip systems offer a more realistic model of human biology than single-organ models.
Organ-on-Chip Technologies to Hasten Transition to Personalized Medicine: Organ-on-chip (OOC) technologies represent a transformative approach in biomedical research that is expected to hasten the transition to personalized medicine. These innovative platforms replicate the microenvironments and functionalities of human organs, allowing for the study of organ-level responses in a controlled setting. By incorporating patient-derived cells or tissues into OOC models, researchers can assess individualized responses to treatments and therapies, paving the way for tailored healthcare solutions. OOC technologies offer several advantages for personalized medicine, including the ability to mimic disease states, evaluate drug efficacy and toxicity with higher accuracy, and optimize treatment strategies based on patient-specific characteristics. Furthermore, OOC platforms enable researchers to explore complex disease mechanisms, identify biomarkers, and develop targeted therapies for precision medicine approaches. As these technologies continue to evolve and gain traction, they hold immense potential to revolutionize healthcare by providing more effective, efficient, and patient-centered solutions.
How can this report add value to an organization?
Product/Innovation Strategy: The global organ-on-chip market has been extensively segmented based on various categories, such as technology, products, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Partnerships, alliances, and collaborations accounted for the maximum number of key developments, i.e., nearly 30.77% of the total developments in the global organ-on-chip market were between January 2021 and April 2024.
Competitive Strategy: The global organ-on-chip market has numerous established players with product portfolios. Key players in the global organ-on-chip market analyzed and profiled in the study involve established players offering organ-on-chip.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research:
The primary sources involve industry experts in the organ-on-chip market, including the market players offering organ-on-chip products. Resources such as CXOs, vice presidents, product managers, directors, territory managers, and business development have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, type portfolio, and market penetration.
Some prominent names in the global organ-on-chip market include:
Scope and Definition